In order to develop a more holistic strategy to hit AD, the same group designed novel MTDLs to target monoamine oxidase A (MAO-A), monoamine oxidase B (MAO-B), lipoxygenase-5 (5-LOX), AChE/BuChE, and σ1 receptors. This evidence concerns the gene MAOA and Alzheimer disease.